PMS69 Key Drivers for Pricing and Reimbursement for Biologic Drugs in France  by Niklitschek, T. et al.
OBJECTIVES: The current analysis evaluates the long-term impacts on household
productivity and social participation of CZP 400mg Q4W combination and mono-
therapy over 5 years. METHODS: In this open-label extension (OLE) (NCT00160693)
patients (pts) originally enrolled in FAST4WARD (NCT00548834) or study 014
(NCT00544154) received CZP 400 mg Q4W for 24 wks. Pts who completed or with-
drew on/after Wk12 in either study were eligible and were permitted to take
DMARDs in OLE. Household productivity and social participation were assessed
through the RA-specific Work Productivity Survey (WPS-RA); results are reported
up to Wk268 (5.2yrs). The analyzed population consisted of (1) Wk 24 CZP com-
pleters from FAST4WARD (N75) or 014 (N96) who entered the OLE (all pts group)
and (2) FAST4WARD CZP completers who entered OLE and did not receive MTX/
DMARDs (N48) (monotherapy subgroup).RESULTS: In both populations analyzed,
a rapid reduction in the number of days of household work days missed per month
was seen from feeder study baseline (BL, 7.4 and 11.1 mean days respectively) over
24wks of the feeder studies to OLE entry (3.5 and 4.1 mean days respectively) and
continued to decline over time, up to Week 268 (1.2 and 1.4 mean days respec-
tively). Increased participation in family/social/leisure activities was reported in
both populations, with a decrease in the number of days missed per month from
feeder study baseline (4.4 and 6.2 mean days, respectively), to entry to OLE, at a
mean of 1.3 and 1.1 days respectively for monotherapy pts; improvements contin-
ued over the 5 years to 0.4 and 0.2 days on average in the 2 populations respectively.
CONCLUSIONS: CZP treatment, in combination with MTX/DMARDs or as mono-
therapy, rapidly decreased the number of household work or social/family/leisure
days missed per month. These improvements were maintained up to 5 years with
open-label CZP following 24 wks double-blind CZP therapy.
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OBJECTIVES: Due to the global economic crisis, most of the actions of the Hungar-
ian government are focused on cost reductions, including in the health care sector.
According to the ownership structure’s changes (i.e., the state becoming the
owner), the most important thing is to create a well-monitored and centralized
hospital system. In addition to these changes, the government seeks to centralize
the procurement of pharmaceuticals and medical equipment at state-owned
hospitals.METHODS:We have prepared literature review and interviews with high
level hospital and political leaders to find how can we strengthen the regulation of
drug consumption at hospitals, which is at this time without strict controls.
RESULTS: Due to the specific objectives of the HunDRG system, which are focused
more on monitoring the number of DRG cases than tracking resources, there are no
incentives for hospitals to maintain strict inventories of their drugs. Except for
biological drugs, which use an itemized financing system, there is no pressure by
the government to monitor the medical costs at the unit level; as such, only hos-
pital data exists. Based on IMS data in 2011, the total hospital sector was valued at
approximately 100 billion HUF. Most of the hospitals do not have adequate com-
puter systems to monitor the patient-level data. CONCLUSIONS: In conclusion, the
so called unit-dose system could be a good solution to measure the drug consump-
tion at the patient level and to improve drug security (trial system). To sum up, it is
very important to gain more data regarding the Hungarian hospital system to be
able to create a sustainable, transparent, highly-regulated, and centralized public
health care system.
PMS69
KEY DRIVERS FOR PRICING AND REIMBURSEMENT FOR BIOLOGIC DRUGS IN
FRANCE
Niklitschek T1, Williams AE2, Storer M3
1University of Cambridge, Cambridge, UK, 2MedImmune Limited, Cambridge, UK, 3PriceSpective,
London, UK
OBJECTIVES: In France, the reimbursement decisions and price negotiations for
new drugs are highly influenced by the National Authority of Health (HAS) recom-
mendations communicated in the formal health technology assessment (HTA).
This study aimed to analyse past criterions and consider future possible require-
ments influencing future submissions.METHODS:A convenient internet literature
review was conducted to identify categories for value drivers in the evaluation of
the incremental medical benefit (ASMR) for a new product. An analysis of five
biological products reviewed 2006-2012 for rheumatology disorders was conducted
using these criterions. Based on the findings, exploratory interviews with two ex-
HAS members were performed to gain insight into future potential evidence
requirements. RESULTS: From the literature review three categories of evidence
were developed. Firstly ‘socioeconomics’, to include the French payers’ perspective
of burden and cost of illness. The second category was ‘clinical evidence’, evaluat-
ing the added therapeutic value for a target population, the clinical efficacy and
safety. The third category was ‘real world data’, to establish effectiveness and
long-term safety post-launch. From the analysis it was demonstrated that only
products targeting patients with an insufficient response to anti-TNFs were rec-
ommended a high -level II- ASMR. Only 2 of 14 phase III studies used an active
comparator in Phase III superiority studies. Open label extension studies were
commonly used to provide post-launch data. Findings of the interviews suggested
that in the future superiority verses current standard of care in France for a clear
target population would be the expectation for an ASMR  IV from the HAS.
CONCLUSIONS: These findings emphasise the need to integrate payer evidence
requirements into the clinical development strategy early on. Effort should be
directed towards the identification of a clear target population demonstrating su-
perior efficacy to standard of care.
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OBJECTIVES: To compare utilization of pain medications between osteoarthritis
(OA) patients initiating duloxetine and standard of care (SOC) after duloxetine’s
approval for OA. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult osteoarthritis patients (ICD-9-CM: 715.xx) initiating duloxetine
or SOC (celecoxib, gabapentin, pregabalin, or venlafaxine) between 11/2010 and
4/2011. Treatment initiation was defined as no pill coverage over 90 days prior, and
first dispense date was defined as index date. Included patients did not use opioids
in 90 days before index date. Propensity score matching was used to select patients
with similar baseline demographic and clinical characteristics for duloxetine and
SOC cohorts. Compliance to index medication was assessed via medication pos-
session ratio (MPR), proportion of days covered (PDC) and proportion discontinued
(a 60-day gap in medication access) for 6 months after index date. Opioids use
after index date was assessed and regression models were estimated to compare
opioid use between cohorts. RESULTS: A total of 1102 patients initiated duloxetine
and 4,302 patients initiated SOC. After matching, 1,021 patients were selected for
duloxetine (mean age: 63 years; female: 79%) and SOC (mean age: 64 years; female:
79%) cohorts, respectively. Duloxetine cohort had significantly higher MPR (0.80 vs.
0.74) and PDC (0.52 vs. 0.43), and were less likely to discontinue initiated medication
(55% vs. 68%) than SOC cohort (all p0.001). Duloxetine cohort was less likely to use
opioids after index date (49% vs. 56%, p0.002), and had fewer days on opioids
(mean: 18 vs. 22, p0.004) than SOC cohort. After adjusting for baseline character-
istics, duloxetine cohort initiated opioids later than SOC cohort (Hazard ratio: 0.85,
95% confidence interval: 0.75-0.97) and had fewer days on opioids (beta: -4.0,
p0.011). CONCLUSIONS: Patients with OA initiating duloxetine were associated
with better compliance to initiated medication and less likely to use opioids than
those initiating SOC.
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OBJECTIVES: To describe utilization patterns of duloxetine and celecoxib and sub-
sequent opioid use among patients with osteoarthritis (OA) after duloxetine’s ap-
proval for OA. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult osteoarthritis patients (ICD-9-CM: 715.xx) who initiated dulox-
etine or celecoxib between 11/2010 and 4/2011. Initiation was defined as no pill
coverage in 90 days prior. Included patients had continuous enrollment in 6
months before and after the initiation and did not use opioid in 90 days before the
initiation. Propensity score matching was used to select patients with similar de-
mographic and clinical characteristics for duloxetine and celecoxib cohorts. Com-
pliance to index medication was assessed via medication possession ratio (MPR),
proportion of days covered (PDC), and proportion discontinued (no access for 60
days). Initiating dose and opioid use after index date was assessed. Cox propor-
tional hazard model was estimated to compare time to first opioid use. RESULTS:A
total of 1360 patients initiated duloxetine and 1,408 patients initiated celecoxib.
After matching, 784 patients were selected for duloxetine (mean age: 66, female:
78%) and celecoxib (mean age: 66; female: 76%) cohorts, respectively. 92.5% of
duloxetine cohort started on 60mg/day, the recommended dose, and 72.8% of
celecoxib cohort started on 200mg/day. Duloxetine cohort had higher MPR and
PDC and a lower proportion of discontinuation than celecoxib cohort (MPR: 0.81 vs.
0.70; PDC: 0.51 vs. 0.35; discontinuation: 57% vs. 78%. all p0.001). A lower propor-
tion of duloxetine cohort used opioids after index date (48.6% vs. 68.5%, p0.001),
and started on opioid later than celecoxib cohort (mean: 132 vs. 107, p0.001). After
controlling for baseline characteristics, duloxetine cohort initiated opioids later
than celecoxib cohort (Hazard ratio: 0.67, 95% confidence interval: 0.58-0.76).
CONCLUSIONS: OA patients initiating duloxetine had better compliance and a
lower likelihood of opioid utilization than those initiating celecoxib.
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OBJECTIVES: Opioids are commonly used to manage chronic pain, including os-
teoarthritis (OA). Duloxetine is approved for OA therapy, but no study has assessed
changes in utilization of opioid therapy following its approval. This study assessed
adherence and the change of opioid use between OA patients who initiated dulox-
etine versus celecoxib. METHODS: Employing administrative claims data, OA pa-
tients aged 18 years who initiated duloxetine or celecoxib between November
2010 and April 2011, and used opioids in 6 months before the initiation, were
identified. Initiation was defined as no access to the same medication over the prior
90 days, and the first dispense date of index medication was denoted as the “index
date”. Patients with80% days covered by index medication during follow-up were
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